Dr. George I. Salti, MD

Dr. Salti practices at Edward Hospital in Naperville, Illinois, part of Endeavor Health.

Dr. Salti's NPI, 1306847702, was assigned on August 9, 2005. Dr. Salti graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1992. Dr. Salti holds Illinois license 036094742.

Dr. Salti's primary practice is Edward Hospital, at 801 South Washington, Naperville, IL 60540 in Du Page County. The practice phone is (630) 527-3000.

Dr. Salti's primary practice is Edward Hospital in Naperville, Illinois, part of Endeavor Health. Dr. Salti is also affiliated with Elmhurst Hospital. The medical group on file is Endeavor Health Medical Group. Dmand AI also links Dr. Salti to 1 more hospital, 4 group practices and clinics, 3 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Salti practices, 8 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Salti's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Salti is licensed in Illinois.

CMS data shows 227 Medicare services from Dr. Salti across 6 procedure codes in 2024, for 191 Medicare patients. Medicare paid $25,883 for them.

CMS counts 191 Medicare patients who saw Dr. Salti in 2024. The largest group is 65 to 74, with 93 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Salti's median patient age at 69, with 55% women.

In 2024, Dr. Salti wrote 81 Medicare Part D claims for 23 patients. 94% of them were for generic drugs. CMS names the drug for 55 of them, across 4 drugs with 11 or more claims each, at $453 in total drug cost. In 2023, CMS named 47 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Salti for performance year 2024, reported as part of a group. Dr. Salti accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 35 procedures of melanoma (skin cancer) excision by Dr. Salti, more than 82% of the clinicians it reports for that procedure.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 49 papers to Dr. Salti, published from 2010 to 2023. 2021 was the busiest year, with 9. The most frequent topics are Cytoreduction Surgical Procedures, Hyperthermia, Induced and Peritoneal Neoplasms. Dr. Salti has published most often in Ann Surg Oncol. Dr. Salti's most frequent co-authors are Samer Alexander Naffouje, MD, Fadi Suhail Dahdaleh, MD and Shanel Balwant Bhagwandin, DO.

Dmand AI links Dr. Salti to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms and Peritoneal Neoplasms.

CMS Open Payments shows 37 general payments to Dr. Salti from 13 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 43% of the total. Medtronic, Inc. paid the most, $1,587.

Dr. Salti graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1992.